Bio-Techne Corporation TECH SPX
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 73.8.
- Earnings shrank at -35.4% CAGR over 5 years.
- Trading 27.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TECH Bio-Techne Corporation SPX | 51.68 | 73.83 | $8.09B | 0.62% | 4.49% | 5.34% | 3.33% | -35.38% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 144.61M | 154.15M | 163.97M | - | 162.97M | 174.51M | 184.86M | - | 183.24M | 184.93M | 194.68M | - | 204.20M | 224.25M | 243.55M | 257.72M | 269.28M | 290.38M | 269.65M | 271.58M | 294.15M | 276.94M | 272.60M | 303.43M | 289.46M | 297.03M | 316.18M | 316.96M | 286.56M | 295.88M | 311.42M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 101.62M | 118.15M | 98.44M | 104.60M | 103.13M |
| Gross Profit | 79.38M | 75.39M | 81.59M | 89.99M | - | 87.34M | 88.14M | 96.68M | - | 97.87M | 101.83M | 110.26M | - | 107.60M | 113.02M | 124.61M | - | 118.41M | 121.40M | 130.06M | - | 137.73M | 150.90M | 168.27M | 171.00M | 183.69M | 201.46M | 179.59M | 183.36M | 202.16M | 185.19M | 176.59M | 204.60M | 183.02M | 193.89M | 214.56M | 198.81M | 188.11M | 191.28M | 208.29M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 175.85M | 82.12M | 140.45M | 136.82M | 132.79M |
| Operating Income | 39.43M | 31.03M | 36.02M | 43.53M | - | 29.16M | 17.88M | 33.50M | - | 26.03M | 24.15M | 43.08M | - | 25.76M | 33.60M | 44.09M | - | 33.33M | 36.99M | 47.79M | - | 49.09M | 50.99M | 68.63M | 63.22M | 62.35M | 90.45M | 56.32M | 67.89M | 80.21M | 55.86M | 38.00M | 67.00M | 39.99M | 47.42M | 38.71M | 116.69M | 47.66M | 54.46M | 75.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 67.85M | 6.43M | 75.27M | 77.66M | 97.80M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.01M | 2.18M | 2.93M | 2.17M | 2.40M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.27M | -22.86M | 47.99M | 50.78M | 71.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.69M | -5.18M | 9.81M | 12.78M | 20.18M |
| Net Income | 24.29M | 22.71M | 25.85M | 30.29M | 25.63M | 18.84M | 7.47M | 22.17M | 27.61M | 15.86M | 48.85M | 19.74M | 41.70M | 17.40M | 17.56M | 44.65M | 16.46M | 14.40M | 119.62M | 36.43M | 58.85M | 33.40M | 46.27M | 45.78M | 69.61M | 80.17M | 60.74M | 89.56M | 50.01M | 70.22M | 50.99M | 27.46M | 49.06M | 33.60M | 34.89M | 22.59M | -17.68M | 38.19M | 38.01M | 51.05M |
| Diluted EPS | 0.65 | 0.61 | 0.69 | 0.81 | 0.69 | 0.50 | 0.20 | 0.59 | 0.74 | 0.42 | 1.29 | 0.52 | 1.07 | 0.45 | 0.45 | 1.15 | 0.42 | 0.37 | 3.02 | 0.92 | 1.48 | 0.83 | 1.15 | 1.12 | 1.69 | 0.49 | 0.37 | 0.55 | 0.31 | 0.43 | 0.31 | 0.17 | 0.31 | 0.21 | 0.22 | 0.14 | -0.11 | 0.24 | 0.24 | 0.32 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 563.00M | 642.99M | 714.01M | 738.69M | 931.03M | 1.11B | 1.14B | 1.16B | 1.22B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 349.10M | 366.89M | 389.33M | 429.36M |
| Gross Profit | 208.03M | 214.15M | 224.94M | 235.80M | 231.11M | 251.41M | 307.28M | 336.66M | 374.54M | 432.14M | 473.49M | 483.19M | 632.85M | 756.50M | 769.82M | 769.73M | 790.27M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 460.67M | 478.82M | 523.32M | 547.47M |
| Operating Income | 150.78M | 156.33M | 163.06M | 166.21M | 158.47K | 159.75M | 147.02M | 150.59M | 120.58M | 136.18M | 146.72M | 157.42M | 237.30M | 295.83M | 291.00M | 246.40M | 242.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 413.76M | 457.11M | 313.14M | 216.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.31M | 11.21M | 15.74M | 8.51M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 301.39M | 338.66M | 185.69M | 98.46M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.29M | 53.22M | 17.58M | 25.06M |
| Net Income | 105.24M | 109.78M | 112.30M | 112.33M | 112.56M | 110.95M | 107.73M | 104.48M | 76.09M | 126.15M | 96.07M | 229.30M | 140.41M | 272.05M | 285.26M | 168.10M | 73.40M |
| Diluted EPS | 2.78 | 2.94 | 3.02 | 3.04 | 3.05 | 3.00 | 2.89 | 2.80 | 2.03 | 3.31 | 2.47 | 5.82 | 0.87 | 1.66 | 1.76 | 1.05 | 0.46 |
Compounded Sales Growth
| 5 Years: | 3.33% |
| 1 Year: | -1.50% |
Compounded Profit Growth
| 5 Years: | -35.38% |
| 1 Year: | 128.60% |
Stock Price Performance
| 1 Year: | +7.42% |
| 6 Months: | -21.27% |
| 3 Months: | -12.24% |
| 1 Month: | -0.34% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 472.00M | 518.82M | 617.67M | 719.32M | 778.10M | 862.49M | 1.06B | 1.13B | 1.56B | 1.59B | 1.88B | 2.03B | - | 2.29B | 2.64B | 2.70B | 2.56B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 605.56M | 621.48M | 617.42M | 608.30M |
| Cash & Equivalents | 166.99M | 160.94M | 94.14M | 77.61M | 116.67M | 163.79M | 318.57M | 54.53M | 64.24M | 91.61M | 121.99M | 100.89M | 146.62M | - | 172.57M | 180.57M | 151.79M | 162.19M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 141.12M | 171.64M | 179.73M | 189.45M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 194.55M | 218.47M | 241.39M | 206.88M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 593.79M | 672.18M | 635.02M | 639.06M |
| Current Liabilities | - | - | 17.02M | 18.19M | 35.75M | 32.08M | 26.39M | 39.77M | 54.15M | 135.52M | 79.51M | 101.98M | 106.67M | - | 176.02M | 128.51M | 159.38M | 175.85M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 243.41M | 350.00M | 319.00M | 346.00M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 325.97M | 454.96M | 419.54M | 444.06M |
| Total Equity | 487.13M | 456.48M | 501.79M | 586.12M | 674.44M | 737.54M | 795.26M | 846.93M | 879.28M | 949.63M | 1.08B | 1.17B | 1.38B | - | 1.70B | 1.97B | 2.07B | 1.92B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 156.64M | 157.64M | 158.22M | 154.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 111.32M | 111.26M | 127.19M | 126.75M | 123.56M | - | - | 144.16M | 143.72M | 170.37M | 181.62M | 205.22M | - | 325.27M | 254.39M | 298.98M | 287.56M |
| Investing Cash Flow | 21.28M | -114.61M | -114.19M | -21.67M | -31.20M | - | - | -107.57M | -305.95M | -38.71M | -336.80M | 27.09M | - | -96.85M | -265.65M | -203.03M | -35.18M |
| Financing Cash Flow | -119.44M | -50.51M | -36.29M | -64.62M | -44.68M | - | - | -23.37M | 189.11M | -99.19M | 134.38M | -183.80M | - | -242.85M | 22.62M | -122.40M | -253.91M |
| Capital Expenditure | -6.56M | -4.64M | -3.63M | -6.02M | -22.45M | -13.82M | -19.91M | -16.90M | -15.18M | -20.93M | -25.41M | -51.74M | - | -44.91M | -38.24M | -62.88M | -31.01M |
| Free Cash Flow | 104.77M | 106.62M | 123.56M | 120.73M | 101.11M | - | - | 127.26M | 128.54M | 149.43M | 156.21M | 153.47M | - | 280.36M | 216.15M | 236.10M | 256.55M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.43M | 11.36M | -26.45M | -1.53M |
| Share Buybacks | 90.63M | 14.97M | 1.94M | 23.60M | 1.82M | 0 | 0 | - | - | 0 | 15.40M | 50.11M | 43.18M | 160.95M | 19.56M | 80.04M | 275.73M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% |
| Operating Margin % | - | - | - | - | - | - | - | - | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 25.6% | 21.3% | 19.9% |
| Net Margin % | - | - | - | - | - | - | - | - | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% |
| ROE % | 23.1% | 21.9% | 19.2% | 16.7% | 15.3% | 14.0% | 12.7% | 11.9% | 8.0% | 11.7% | 8.2% | 16.6% | - | 16.0% | 14.5% | 8.1% | 3.8% |
| ROCE % | - | 31.2% | 27.2% | 24.3% | 0.0% | 19.1% | 14.4% | 14.0% | 8.5% | 9.0% | 8.2% | 8.2% | - | 14.0% | 11.6% | 9.7% | 10.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.83% | 12.26M | $633.83M |
| 2 | Vanguard Capital Management LLC | 6.50% | 10.18M | $526.09M |
| 3 | Morgan Stanley | 5.45% | 8.53M | $440.98M |
| 4 | FMR, LLC | 5.05% | 7.90M | $408.27M |
| 5 | Vanguard Portfolio Management LLC | 4.14% | 6.48M | $334.90M |
| 6 | State Street Corporation | 3.75% | 5.87M | $303.28M |
| 7 | Wellington Management Group, LLP | 3.27% | 5.12M | $264.61M |
| 8 | Geode Capital Management, LLC | 3.27% | 5.11M | $264.21M |
| 9 | Maverick Capital Ltd. | 3.03% | 4.74M | $244.95M |
| 10 | Invesco Ltd. | 2.93% | 4.59M | $237.14M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TECH
How one founder’s bet on ‘the old school web’ is paying off
Craig Campbell walked away from the river of investor money flowing into AI to create, of all things, a website. Sure, Campbell probably could have started an AI company. He's a former engineer at Met…
Tech companies desperately want to film you doing chores
This week, an AI training startup called Shift said it would clean New Yorkers' homes for free. It has plans to expand into other cities as well, including London, and looking around my flat, I get th…
The Download: climate tech goes public and the AI Hype Index returns
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Climate tech companies are going public. What’s ne…
Climate tech companies are going public. What’s next?
This year, there’s been a wave of notable energy companies going public via IPO in the US. The solar and battery company Solv Energy went public in February, to the tune of $6 billion. X-energy, which…